Hatzidakis Adam, Müller Lukas, Krokidis Miltiadis, Kloeckner Roman
Department of Radiology, AHEPA University Hospital of Thessaloniki, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Cancers (Basel). 2022 May 17;14(10):2469. doi: 10.3390/cancers14102469.
Hepatocellular carcinoma (HCC) can be treated by local and regional methods of percutaneous interventional radiological techniques. Indications depend on tumor size, type and stage, as well as patient's condition, liver function and co-morbidities. According to international classification systems such as Barcelona Clinic Liver Cancer (BCLC) classification, very early, early or intermediate staged tumors can be treated either with ablative methods or with transarterial chemoembolization (TACE), depending on tumor characteristics. The combination of both allows for individualized forms of treatment with the ultimate goal of improving response and survival. In recent years, a lot of research has been carried out in combining locoregional approaches with immune therapy. Although recent developments in systemic treatment, especially immunotherapy, seem quite promising and have expanded possible combined treatment options, there is still not enough evidence in their favor. The aim of this review is to provide a comprehensive up-to-date overview of all these techniques, explaining indications, contraindications, technical problems, outcomes, results and complications. Moreover, combinations of percutaneous treatment with each other or with immunotherapy and future options will be discussed. Use of all those methods as down-staging or bridging solutions until surgery or transplantation are taken into consideration will also be reviewed.
Local and regional therapies remain a mainstay of curative and palliative treatment of patients with HCC. Currently, evidence on potential combination of the local and regional treatment options with each other as well as with other treatment modalities is growing and has the potential to further individualize HCC therapy. To identify the most suitable treatment option out of these new various options, a repeated interdisciplinary discussion of each case by the tumor board is of utmost importance.
肝细胞癌(HCC)可通过经皮介入放射技术的局部和区域方法进行治疗。适应证取决于肿瘤大小、类型和分期,以及患者的病情、肝功能和合并症。根据国际分类系统,如巴塞罗那临床肝癌(BCLC)分类,极早期、早期或中期肿瘤可根据肿瘤特征采用消融方法或经动脉化疗栓塞(TACE)进行治疗。两者结合可实现个体化治疗形式,最终目标是提高反应率和生存率。近年来,在将局部区域治疗方法与免疫治疗相结合方面开展了大量研究。尽管全身治疗,尤其是免疫治疗的最新进展似乎很有前景,并扩大了可能的联合治疗选择,但仍缺乏足够的证据支持。本综述的目的是对所有这些技术提供全面的最新概述,解释适应证、禁忌证、技术问题、结果、疗效和并发症。此外,还将讨论经皮治疗相互之间或与免疫治疗的联合应用以及未来的选择。还将回顾在考虑手术或移植之前将所有这些方法用作降期或桥接解决方案的情况。
局部和区域治疗仍然是HCC患者治愈性和姑息性治疗的主要手段。目前,关于局部和区域治疗方案相互之间以及与其他治疗方式潜在联合应用的证据正在增加,并且有可能进一步使HCC治疗个体化。为了从这些新的各种选择中确定最合适的治疗方案,肿瘤委员会对每个病例进行反复的多学科讨论至关重要。